Yahoo Web Search

Search results

1. • Affimed's AFM24 With Atezolizumab For EGFR Wild-Type NSCLC Gets FDA Fast Track Status; Stock Up

     RTT News· 2 days ago

     Affimed N.V. (AFMD), a clinical-stage immuno-oncology company, Wednesday announced that it has received Fast Track Designation from the U.S. Food and Drug Administration for combination < ...

2. • Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction further...

     NBC 17 Raleigh· 6 days ago

     ...proteinuria in IgAN2-5; atrasentan is a potent, selective ETA receptor antagonist with potential to reduce persistent proteinuria and preserve kidney function for a broad patient population1IgAN is a heterogeneous, progressive, rare kidney disease with a need for effective, targeted therapies6,7;...

3. • HI-Bio Announces Positive Results from Phase 2 Study of Felzartamab for Late Antibody-Mediated...

     KSAN - KLST San Angelo· 6 days ago

     ...n=9/11) of patients on felzartamab experienced resolution of antibody-mediated rejection per Banff criteria on biopsy at 24 weeks versus 20% (n=2/10) who received placebo, and patients treated with felzartamab showed reductions in disease-linked biomarkers and stabilization of eGFR 63% (n=7/11)...

4. • 

     Drug resistance discovery could 'move the field forward' for breast cancer treatment

     Medical Xpress· 2 days ago

     Additionally, the research team tested a promising drug in combination with an existing therapy that...

5. • Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing...

     KTLA-TV Los Angeles· 6 days ago

     Novartis today presented results from the 6-month, double-blind period of the Phase III APPEAR-C3G study of Fabhalta® (iptacopan) at the late-breaking clinical trials session of the European ...

6. • 

     All Over the Map? Mechanisms of ICI Acquired Resistance in NSCLC

     MedPage Today· 7 days ago

     "Resistance is futile." What's less debatable, though, is that patients with non-small cell lung...

7. • PH-binding motifs as a platform for drug design: Lessons from protease-activated receptors

     Medical Xpress· 7 days ago

     A new editorial paper was published in Oncoscience, titled "PH-binding motifs as a platform for drug design: Lessons from protease-activated receptors; PARs."

8. • 

     H.C. Wainwright lowers Ikena Oncology shares target amid IK-930 halt By Investing.com

     Investing.com· 2 days ago

     On Wednesday, H.C. Wainwright adjusted its outlook on Ikena Oncology (NASDAQ:IKNA) shares,...

9. • 

     Scientists uncover new treatment pathway for rare 'spider web' childhood brain tumors

     Medical Xpress· 7 days ago

     A decade-long study, carried out by a team from The Institute of Cancer Research, London, as part of...

10. • 

      Calliditas Therapeutics Presents Data at the 61st European Renal Association Congress

      WTNH-TV New Haven· 3 days ago

      The presented efficacy analysis of Nefecon and sparsentan showed that treatment with Nefecon for 9...